It argues that the combination could theoretically work based on separately demonstrated evidence for digital therapeutics and cannabis, but the combined approach has never been tested in any patient population. This commentary contributes a clearly articulated conceptual framework for integrating medical cannabis with prescription digital therapeutics and accurately identifies the structural failures of current cannabis care. It does not establish that the proposed Smart Cannabis model is effective, safe, feasible, equitable, or implementable within current regulatory structures. The research agenda the paper implies, particularly feasibility pilots and controlled comparisons, is genuinely worth pursuing.

#Building a Digital Therapeutics Conference Staffing Program

Policy recommendations include Smart Cannabis pilot programs, improved product labeling, bundled reimbursement models, and clinician education. The authors briefly acknowledge that smartphone-only tools may lack the physiological precision https://8wsm.com/travel-amp-tourism/why-there-s-no-sound-in-space/ necessary for true feedback-driven dosing and that wearable technology requirements could introduce equity barriers. They are transparent that the model is aspirational and requires empirical validation, though the extent of that gap is arguably understated given the confident framing of their proposal.

Industry Overview

Virta Health is a technology-enabled healthcare company that focuses on the reversal of type 2 diabetes and other metabolic conditions without medication or surgery. The company utilizes a “treatment-as-a-service” model that combines a specialized ketogenic nutritional protocol with continuous remote monitoring and human coaching. Virta’s approach has demonstrated significant clinical success in reducing A1c levels and eliminating insulin dependence for a high percentage of its members.

Related Reports

This new category—Digital Therapeutics (DTx)—uses evidence-based software programs to prevent, manage, or treat diseases. Combined with Clinical AI, predictive analytics, behavioral science, and real-time patient monitoring, digital therapeutics are rapidly reshaping healthcare delivery worldwide. Oncology represents a significant opportunity for software-enhanced drugs, especially in treatment adherence, symptom management, and quality of life improvement. Cancer treatments often involve complex regimens with significant side effects, making them ideal candidates for software enhancement.

There is no standardized dosing, no integrated electronic health record documentation, and virtually no closed-loop feedback between patient response and treatment adjustment. At a time when cannabis legalization is accelerating and digital https://thermohistory.org/the-discovery-and-applications-of-infrared-radiation/ health tools are gaining FDA clearance for a growing list of conditions, the question of whether these two trajectories can be linked is clinically urgent. This commentary forces that question into focus, even if it cannot yet provide the answer.

• Business models range from direct-to-consumer offerings to partnerships with hospitals, employers, and payers.
• Get the latest insights on experiential marketing trends and exclusive event invitations.
• Digital therapeutics play an important role in the healthcare ecosystem alongside clinician-delivered care, pharmaceuticals, and other non-DTx medical devices.
• The software component can improve patient outcomes while increasing the likelihood of drug adherence, creating a synergistic effect that benefits both patient health and commercial success.
• Currently, there is no standard way to define what constitutes meaningful engagement and how to compare engagement across different digital therapeutic devices (21).

Industry leaders like ResMed Inc. are innovating with products such as the AirCurve 11 series, a bilevel device providing dual-pressure support for effective sleep apnea therapy. Such advances offer features like secure data transfer, automatic software updates, and robust patient engagement tools, improving both patient experience and therapy compliance. Digital therapeutics represent a major shift toward more accessible, personalized, and technology-driven healthcare, improving outcomes for patients around the world. Because this is a commentary rather than an empirical study, the relevant question is not about statistical analysis but about argumentative choices.

Improved Adherence through Behavioral Interventions

• Each of these therapeutic areas represents opportunities for pharmaceutical companies to enhance existing portfolios and potential entry points into new markets.
• Biofourmis partners with health systems and pharmaceutical companies to deliver “hospital-at-home” programs and enhance the efficacy of drug therapies through digital augmentation.
• This approach has enabled the patient’s own body to produce CAR-T therapies internally, potentially removing the need for complex external cell manufacturing.
• But one study of 93 non-FDA approved Android apps (median installs 100,000), targeting mental wellbeing, found the medians of app 15 and 30-day retention rates were very low at 3.9% and 3.3% (23).
• While DTA does not endorse, certify, or accredit products, we are glad to provide examples of DTx products from member companies that attest to aligning with DTx Industry Core Principles.

Cannabis interacts with numerous medications through cytochrome P450 pathways, and any real-time dosing guidance system would need to account for these interactions, a technical challenge the commentary does not address. The privacy implications of digitally tracking a federally scheduled substance are substantial and remain unexplored. Clinicians should continue to use existing structured approaches to cannabis care, including careful documentation, patient-reported outcome tracking, and regular follow-up visits.

Behavioral Health Platforms

The digital health ecosystem includes a diverse landscape of fitness and wellness apps, AI-enabled diagnostics, telemedicine platforms, companion apps, prescription digital therapeutics, and software-enhanced drugs. Products within this ecosystem require some degree of data security and validation, but a subset that are intended to identify or treat disease also require extensive clinical evidence and regulatory clearance. Business models range from direct-to-consumer offerings to partnerships with hospitals, employers, and payers. Biofourmis is a global technology-enabled care delivery company that uses AI and machine learning to provide personalized remote patient monitoring and digital therapeutics.

• The Japan Overactive Bladder (OAB) therapeutics market is poised for expansion through innovative strategies including cross-industry collaborations and ecosystem partnerships.
• They expect informed answers for their medical and health technology-related questions from their physicians.8 In such an aware world, the need for digital health and related tools becomes inevitable.
• Even effective apps will have limited impact if they are not highly engaging and result in high attrition (18, 19).
• No validated real-time biomarker for cannabinoid effect exists, and subjective symptom scores used as proxies are vulnerable to expectancy bias, reporting inconsistency, and placebo effects.
• This expansion reflects DTx technology’s maturation and the pharmaceutical industry’s recognition of software’s potential to address previously unmet clinical needs.

Individual countries often set different requirements for which products require a formal prescription. An industry-defining alliance fostering a more effective and inclusive community for advancing tech-enabled and virtual care. Our articles may be redistributed for online commercial purposes, provided you link back to Panabee.com and provide attribution.

Companies that recognize digital as the future of medicine and act accordingly will be best positioned to serve patients and succeed in an increasingly competitive healthcare marketplace. These products leverage established behavioral science principles, incorporating evidence-based approaches like cognitive behavioral therapy and dialectical behavior therapy. They may be further enhanced through gamification principles that boost patient adherence and AI-powered personalization engines that can adapt treatment protocols to individual patient needs and responses. Given the proliferation of products available to patients, caregivers, and clinicians for use in healthcare, it can be difficult for end users to determine which products are digital therapeutics versus other types of DHTs. This flowchart helps healthcare decision makers and end users understand which products qualify as a digital therapeutic.